Equities researchers at Rodman & Renshaw started coverage on shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) in a research report issued on Monday. The firm set a “buy” rating and a $5.00 price target on the specialty pharmaceutical company’s stock. Rodman & Renshaw’s price objective indicates a potential upside of 80.51% from the stock’s current price.

Imprimis Pharmaceuticals (NASDAQ:IMMY) opened at 2.77 on Monday. The company’s market cap is $36.71 million. The stock has a 50 day moving average of $2.78 and a 200-day moving average of $3.61. Imprimis Pharmaceuticals has a 12 month low of $2.22 and a 12 month high of $7.81.

ILLEGAL ACTIVITY WARNING: “Rodman & Renshaw Initiates Coverage on Imprimis Pharmaceuticals Inc. (IMMY)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/30/rodman-renshaw-initiates-coverage-on-imprimis-pharmaceuticals-inc-immy.html.

A number of institutional investors have recently bought and sold shares of the stock. Berson & Corrado Investment Advisors LLC bought a new position in Imprimis Pharmaceuticals during the second quarter valued at $117,000. BlackRock Fund Advisors raised its position in Imprimis Pharmaceuticals by 59.5% in the second quarter. BlackRock Fund Advisors now owns 32,979 shares of the specialty pharmaceutical company’s stock valued at $124,000 after buying an additional 12,300 shares during the last quarter. Northern Trust Corp raised its position in Imprimis Pharmaceuticals by 4.1% in the third quarter. Northern Trust Corp now owns 45,467 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 1,800 shares during the last quarter. Granite Investment Partners LLC raised its position in Imprimis Pharmaceuticals by 3.7% in the third quarter. Granite Investment Partners LLC now owns 160,876 shares of the specialty pharmaceutical company’s stock valued at $613,000 after buying an additional 5,686 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Imprimis Pharmaceuticals by 1.7% in the second quarter. Vanguard Group Inc. now owns 168,584 shares of the specialty pharmaceutical company’s stock valued at $634,000 after buying an additional 2,831 shares during the last quarter. Institutional investors own 24.85% of the company’s stock.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

5 Day Chart for NASDAQ:IMMY

Receive News & Stock Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.